A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the VC had previously enjoyed a rewarding exit, but in light of the high level of uncertainties associated with neurological conditions requested an independent third party expert view.
The assignment was conducted by a senior pharmaceutical neurologist with whom Alacrita has worked on numerous occasions over the past ten years. He examined the scientific rationale, the preclinical proof-of-principle, the proposed biomarkers and the design of clinical trials though to licensure and concluded that the projects were well thought-through with a sound understanding of the (high) associated risks. Following the assignment, the target company requested ongoing support from Alacrita in the area of European regulatory affairs.
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.